

O. Bamigbola<sup>1</sup> , C. Bates<sup>1</sup> and L. Warwick<sup>2</sup>

1. Lymphoma Coalition, Research, Mississauga, ON, Canada | 2. Lymphoma Coalition, Management, Mississauga, ON, Canada

**INTRODUCTION**

- Hodgkin lymphoma (HL) which often affects young adults, has one of the highest cure rates among all cancers and as such, an increasing number of survivors each year.
- Its treatment may cause long-term or late effects which can affect the patient’s overall health and quality of life, however not much is known about the impact that age has on the patient’s experience and management of these effects.
- Using data from the Lymphoma Coalition (LC) 2022 Global Patient Survey (GPS) on Lymphomas and CLL, this study examines the impact of ageing on the survivorship experiences of patients with HL who were in remission.

**METHODS**

**Study design**

- This study is a sub-analysis of the LC 2022 GPS, which is an online global survey of patients with lymphoma and CLL, carried out every two years
- The LC 2022 GPS was hosted on a third-party portal from February- April 2022 in 19 languages

**Respondents**

- Globally, there were 8,637 respondents from 70+ countries (7,113 patients and 1,524 caregivers), including **851 patients who had HL and 447** of them identified as being **in remission**.
- The patients in remission were grouped into two age groups for analysis, based on their current age at survey time: **18-39yrs (n=248) and 40yrs+ (n=199)**.

**Statistical analysis**

- The demographics of both groups were examined, and univariate and bivariate analyses of questions relating to patients’ support experiences were performed in IBM SPSS v27.

**RESULTS**

Patients were asked which psychosocial issues they had experienced over the last 12 months because of their lymphoma. The older age group (40+) reported the lowest prevalence of every psychosocial issue listed (Table 1). The older age group (40+) also reported the highest prevalence of experiencing no psychosocial issues ('none') (19%). Fear of relapse of HL was the most prevalent psychosocial issue in both age groups (18-39- 80% and 40+- 63%) (**Table 1**).

Patients who reported experiencing symptoms of HL and/or side effects of treatment were asked how these symptoms and/or side effects impacted their life, including everyday activities, employment, social life, and relationships (Table 1). Both age groups differed significantly in how they experienced these impacts with the lowest prevalence for each of these impact categories being observed in the older age group (40+) (**Table 1**).

When asked about their transition from cancer care into survivorship, patients in both groups had similar experiences in the areas of follow-up visits, knowledge of whom to contact about health issues, and feeling supported, but differed in their knowledge regarding their personal post-treatment care plan (**Table 1**). About half of patients in both groups felt as supported in their survivorship experience as when they were receiving active care.

**CONCLUSION**

Compared to the older survivors, younger survivors with HL are disproportionately affected by psychosocial issues and are more impacted by the effect of their symptoms and side effects.

Addressing the psychosocial and support needs of all HL survivors should be a key part of their care and it is important for health care providers to know that younger patients may require additional attention and support.

**Younger survivors with Hodgkin lymphoma are disproportionately affected by psychosocial issues and are more impacted by the effect of their symptoms and side effects compared to older survivors.**

**Only half of patients in both age groups felt as supported in their survivorship experience as when they were receiving active care.**

Table 1. Survivorship experience of patients with Hodgkin lymphoma

	18-39 yrs (%)	40 yrs + (%)	X2 (p-value)
<b>Prevalence of psychosocial issues experienced in the last 12 months</b>			
Loss of self-esteem	34%	24%	4.21 (0.04)
Post-traumatic stress disorder	28%	15%	9.80 (0.002)
Concerns about physical appearance	49%	31%	12.85 (<0.001)
Changes in relationships	25%	18%	2.12 (0.15)
Isolation	32%	23%	4.06 (0.04)
Depression	30%	25%	1.02 (0.31)
Anxiety	55%	33%	18.58 (p<0.001)
Fear of relapse of lymphoma	80%	63%	13.11 (p<0.001)
No psychosocial issues experienced	8%	19 %	11.40 (p<0.001)
<b>Impact of lymphoma symptoms and treatment side effects</b>			
	18-39 yrs (%)*	40 yrs + (%)*	X2 (p-value) *
My symptoms and/ or side effects have negatively impacted everyday activities that people my age can usually do (e.g., exercise, shopping, household chores)	82%	75%	20.30 (0.001)
I have been unable to work/had to change my job or working pattern because of my symptoms and/or side effects	69%	57%	19.58 (0.002)
My symptoms and/or side effects have had a negative impact on my social life	73%	57%	21.46 (<0.001)
My symptoms and/or side effects have had a negative impact on my partner, children, close friends, or relatives	65%	57%	12.90 (0.02)
<b>Healthcare changes experienced transitioning from active cancer care into survivorship</b>			
	18-39 yrs (%)*	40 yrs + (%)*	X2 (p value) *
There is a post-treatment care plan (e.g., survivorship care plan)	54%	69%	11.07 (0.03)
There are regular follow-up visits with a lymphoma/CLL care provider	93%	87%	4.7 (0.32)
I know who to contact about different health issues that may be experienced	78%	76%	1.35 (0.85)
I feel as supported now as when receiving active care for lymphoma	48%	50%	3.27 (0.51)

\*Chi-square values calculated are based on the inclusion of all question response options, though only the percentages for those who 'strongly agree or agree' are displayed in the table.

**CONFLICT-OF-INTEREST DISCLOSURES AND CONTACT INFORMATION**

Study was sponsored by Pfizer Inc, AbbVie Corporation and Takeda Oncology. None of the authors benefited personally from the research.

For further details on the LC 2022 GPS, please scan the QR code or visit:  
<https://lymphomacoalition.org/global-patient-survey/>.

Please direct any queries to the research department at Lymphoma Coalition:  
[funmi@lymphomacoalition.org](mailto:funmi@lymphomacoalition.org) or [cherie@lymphomacoalition.org](mailto:cherie@lymphomacoalition.org)